By Fineline Cube 
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its innovative antibody drug conjugate (ADC) ICP-B794 targeting B7-H3.
ICP-B794: Mechanism and Advantages
ICP-B794 comprises a humanized anti-B7-H3 monoclonal antibody conjugated via a protease-cleavable linker to a potent payload independently developed by InnoCare. This innovative ADC is designed to enhance precision targeting of tumor cells while minimizing off-target effects.
B7-H3 and Therapeutic Potential
B7-H3, a type I transmembrane protein, is highly expressed in various solid tumors. Currently, no B7-H3-targeting therapies have been approved globally. ICP-B794 holds potential for treating multiple cancers, including lung cancer, esophageal cancer, nasopharyngeal carcinoma, prostate cancer, and head and neck squamous cell carcinoma.
InnoCare’s ADC Platform
InnoCare stated that it will leverage its ADC platform to continue developing differentiated drug candidates, enriching its pipeline portfolio, and advancing precision medicine in solid tumor treatment.-Fineline Info & Tech